In the past 12 months, which of these trials have you heard about? (Select all that apply)
Are you employed by or affiliated with ... ?
How many adult patients patients do you manage with this condition eeting these criteria?
Response #1--In the past 3 months, list any new information you have heard in regards to cardiovascular outcomes for type 2 diabetes medications?
Response #2--In the past 3 months, list any new information you have heard in regards to cardiovascular outcomes for type 2 diabetes medications?
Response #3--In the past 3 months, list any new information you have heard in regards to cardiovascular outcomes for type 2 diabetes medications?
GLP-1 agonist class--What proportion of your patients do you treat with the following products?
DPP-4 inhibitor class--What proportion of your patients do you treat with the following products?
Xooft (trianaflozin)--What proportion of your patients do you treat with the following products?
Juvoxan (julixapril)--What proportion of your patients do you treat with the following products?
Other products/classes--What proportion of your patients do you treat with the following products?
GLP-1 agonist class--Based on this new information please indicate whether you will increase/decrease/remain the same your prescribing of the following products/classes for your patients
DPP-4 inhibitor class--Based on this new information please indicate whether you will increase/decrease/remain the same your prescribing of the following products/classes for your patients
Xooft (trianaflozin)--Based on this new information please indicate whether you will increase/decrease/remain the same your prescribing of the following products/classes for your patients
Juvoxan (julixapril)--Based on this new information please indicate whether you will increase/decrease/remain the same your prescribing of the following products/classes for your patients
Other products/class--Based on this new information please indicate whether you will increase/decrease/remain the same your prescribing of the following products/classes for your patients
GLP-1 agonist class--For those products/classes that you indicated that you will increase your prescribing, by what percent will you increase each product/class?
DPP-4 inhibitor class--For those products/classes that you indicated that you will increase your prescribing, by what percent will you increase each product/class?
Xooft (trianaflozin)--For those products/classes that you indicated that you will increase your prescribing, by what percent will you increase each product/class?
Juvoxan (julixapril)--For those products/classes that you indicated that you will increase your prescribing, by what percent will you increase each product/class?
Any other products/classes--For those products/classes that you indicated that you will increase your prescribing, by what percent will you increase each product/class?
GLP-1 agonist class--For those products/classes that you indicated that you will decrease your prescribing, by what percent will you decrease each product/class?
DPP-4 inhibitor class--For those products/classes that you indicated that you will decrease your prescribing, by what percent will you decrease each product/class?
Xooft (trianaflozin)--For those products/classes that you indicated that you will decrease your prescribing, by what percent will you decrease each product/class?
Juvoxan (julixapril)--For those products/classes that you indicated that you will decrease your prescribing, by what percent will you decrease each product/class?
Other products/classes--For those products/classes that you indicated that you will decrease your prescribing, by what percent will you decrease each product/class?